Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

9.9K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
9.9K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

3.7K
3.7K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

18.8K
The eukaryotic promoter region is a segment of DNA located upstream of a gene. It contains an RNA polymerase binding site, a transcription start site, and several cis-regulatory sequences.  The proximal promoter region is located in the vicinity of the gene and has cis-regulatory sequences and the core promoter. The core promoter is the binding site for RNA polymerase and is usually located between -35 and +35 nucleotides from the transcription start site. The distal promoter regions are...
18.8K
The Eukaryotic Promoter Region02:40

The Eukaryotic Promoter Region

3.9K
3.9K
PD Controller: Design01:26

PD Controller: Design

655
In automotive engineering, car suspension systems often employ Proportional Derivative (PD) controllers to enhance performance. PD controllers are utilized to adjust the damping force in response to road conditions. A controller, acting as an amplifier with a constant gain, demonstrates proportional control, with output directly mirroring input.
Designing a continuous-data controller requires selecting and linking components like adders and integrators, which are fundamental in Proportional,...
655
Time-Domain Interpretation of PD Control01:07

Time-Domain Interpretation of PD Control

405
Proportional-Derivative (PD) control is a widely used control method in various engineering systems to enhance stability and performance. In a system with only proportional control, common issues include high maximum overshoot and oscillation, observed in both the error signal and its rate of change. This behavior can be divided into three distinct phases: initial overshoot, subsequent undershoot, and gradual stabilization.
Consider the example of control of motor torque. Initially, a positive...
405

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Major form of NUP98/HOXC11 fusion in adult AML with t(11;12)(p15;q13) translocation exhibits aberrant trans-regulatory activity.

Leukemia·2003
Same author

[Fluoride-oxide glass for high efficiency upconversion from IR to green].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[In situ IR study of the reaction behavior of clusters [VnCr3-n (mu 3-O) (mu-O2CCH3)6(THF)3]X[n = 0-3, X = Cl-, ClO4-, (VO5)0.5-] and [VnFe3-n(mu 3-O) (mu-O2CCH3)6(THF)3]X(n = 0-3, X = Cl-) in nitrogen atmosphere].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[In situ IR study of the reaction behavior of transition metal oxides-propionic acid system, Fe2Cr(mu 3-O) (mu-O2CC2H5)6(H2O)3Cl.xH2O and Cr3 (mu 3-O) (mu-O2CC2H5)6(H2O)3NO3.xH2O].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[Monte Carlo simulation of FCS in a laser gradient field].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same author

[A study on the concentration quenching of Tm3+ upconversion luminescence].

Guang pu xue yu guang pu fen xi = Guang pu·2003
Same journal

Retraction Note: Can the endometrioma be an obstacle to complete oocyte retrieval in IVF cycles? A retrospective study.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: A multicenter clinical study with myo-inositol and alpha-lactalbumin in Mexican and Italian PCOS patients.

European review for medical and pharmacological sciences·2026
Same journal

Retraction Note: Oxycodone inhibits myocardial cell apoptosis after myocardial ischemia-reperfusion injury in rats via RhoA/ROCK1 signaling pathway.

European review for medical and pharmacological sciences·2026
Same journal

Intracoronary stem cell transplant in ischemic heart disease: a meta-analysis of randomized trials.

European review for medical and pharmacological sciences·2026
Same journal

From models to medicine: advanced preclinical systems and AI enabling RNA therapeutics in triple-negative breast cancer.

European review for medical and pharmacological sciences·2026
Same journal

Association of serum asprosin levels with obesity indices and metabolic parameters in adults.

European review for medical and pharmacological sciences·2026
See all related articles

Related Experiment Video

Updated: Feb 1, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K

LncRNA-UCA1 promotes PD development by upregulating SNCA.

M Lu1, W-L Sun, J Shen

  • 1Department of Rehabilitation Medicine, Huai'an First People's Hospital, Nanjing Medical University, Huai'an, China. dmqr43@163.com.

European Review for Medical and Pharmacological Sciences
|December 12, 2018
PubMed
Summary
This summary is machine-generated.

Long non-coding RNA UCA1 promotes Parkinson's disease (PD) progression by increasing alpha-synuclein (SNCA) expression. This study reveals UCA1 as a potential therapeutic target for PD.

More Related Videos

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Related Experiment Videos

Last Updated: Feb 1, 2026

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

1.2K
Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
09:11

Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma

Published on: May 24, 2024

1.2K

Area of Science:

  • Neuroscience
  • Molecular Biology
  • Genetics

Background:

  • Parkinson's disease (PD) is a progressive neurodegenerative disorder.
  • Alpha-synuclein (SNCA) aggregation is a key pathological hallmark of PD.
  • The role of long non-coding RNAs (lncRNAs) in PD pathogenesis is an emerging area of research.

Purpose of the Study:

  • To investigate the role of lncRNA-UCA1 in the regulation of SNCA expression.
  • To determine if lncRNA-UCA1 influences the progression of Parkinson's disease.

Main Methods:

  • Established PD mouse and in vitro cell models using MPTP and MPP+ respectively.
  • Quantified UCA1 and SNCA expression via qRT-PCR and Western blot.
  • Assessed cell viability, apoptosis, and SNCA levels following UCA1 manipulation.

Main Results:

  • UCA1 and SNCA were upregulated in PD models.
  • UCA1 overexpression increased SNCA mRNA and protein levels.
  • UCA1 knockdown enhanced cell viability and reduced neuronal apoptosis in MPP+-treated cells.

Conclusions:

  • LncRNA-UCA1 promotes PD occurrence and progression.
  • Upregulation of SNCA expression by UCA1 is a key mechanism in PD pathogenesis.
  • Targeting UCA1 may offer a novel therapeutic strategy for Parkinson's disease.